Clinical trial
Alendronate to Prevent Perimenopausal Transition Bone Loss
NCT00221312 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Alendronate to Prevent Perimenopausal Transition Bone Loss
- Lead sponsor
- University of California, San Francisco
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 31, 2002
- Completion date
- July 31, 2007
- Enrollment
- 48 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
perimenopausal bone loss